Tirzepatide Clinical Trials: Reading the Evidence Behind Mounjaro and What It Leaves Open

If you've read about tirzepatide clinical trials lately, you've probably seen headlines packed with percentages. Blood sugar drops, weight changes, comparisons with semaglutide. Those numbers matter, but they only make sense once you know how each study was built. This post walks through the research behind Mounjaro, focusing on the SURPASS-2 and SURMOUNT-1 trials, and explains what they show and what they leave open.

Why trial names and numbers matter when you read about Mounjaro

Most news stories quote one result and move on. They rarely tell you who was studied, how long the study lasted, or what the drug was compared against. Those details can change the meaning of a number completely. A weight change in adults with obesity and no diabetes tells a different story than a blood sugar change in adults with type 2 diabetes.

It helps to know the stages a drug goes through. Early work often happens in animals, which tells researchers about biology but not about how people respond. Phase 2 studies in people look at dose and safety in smaller groups. Phase 3 studies are larger and longer. SURPASS-2 and SURMOUNT-1 are phase 3 randomized clinical trials, meaning participants were assigned to treatment groups by chance. That randomization lets researchers compare groups fairly, because the groups differ mainly in what they received.

You can check any of this yourself. Start at ClinicalTrials.gov, the public registry where trials are listed. The SURPASS-2 entry is NCT04037566 and the SURMOUNT-1 entry is NCT04184622. Compare each registry page with the published paper. Look at the eligibility criteria, the planned duration, and the listed outcomes. Confirm the registration numbers on the registry page itself before you repeat them anywhere, because numbers get copied wrong all the time. Reading guides on this blog can speed up the process, and a pharmacist can help you sort out terms you don't recognize.

What the receptor research tells us about GIP and GLP-1

Researchers studied GLP-1 and GIP for years before tirzepatide existed. Much of the early science came from laboratory and animal work. That kind of work can point to useful questions, but it doesn't predict how people will respond, so it works best as a starting point rather than a conclusion.

Some researchers have asked whether GIP signaling helps or hurts weight control, and whether its effects on appetite and insulin release add to what GLP-1 does. These are open research questions. The trials were not designed to settle which mechanism matters most, and nobody should treat a single hypothesis as established fact.

Tirzepatide is a dual agonist, which means it binds to and activates both the GIP and GLP-1 receptors. The U.S. prescribing information describes it this way, and you can read the full label in the FDA label for Mounjaro. Labels get updated over time, so check the current version on the Anvisa bulário eletrônico for the Brazilian version.

SURPASS-2: tirzepatide compared with semaglutide in type 2 diabetes

SURPASS-2 is the study people usually mean when they ask whether tirzepatide works better than semaglutide. Frías and colleagues published it in the New England Journal of Medicine in 2021, and the full paper is available by DOI. Adults with type 2 diabetes were randomly assigned to one of three tirzepatide doses (5 mg, 10 mg, or 15 mg) or to semaglutide 1 mg. This was a direct comparison, not a comparison against placebo alone. The main outcome was the change in HbA1c, a measure of average blood sugar over about three months, at the end of treatment.

All three tirzepatide doses lowered HbA1c more than semaglutide did, and the highest dose produced the largest average drop. Check the exact figures and the study length of 40 weeks in the results section of the paper, since the abstract gives only a summary. A bigger average is not the same as a better fit for every person, though. Trial doses follow a fixed schedule, while real prescribing usually starts low and adjusts based on response and side effects.

Gastrointestinal events were the most frequently reported adverse events. The authors describe them as more common during dose escalation and at higher doses. Read the adverse events table yourself, because the rates differ by dose and by group, and a summary can flatten those differences.

SURMOUNT-1: what the weight results looked like in adults with obesity

SURMOUNT-1, led by Jastreboff and colleagues and published in the New England Journal of Medicine in 2022, asked a different question. Participants had obesity, or overweight plus at least one weight-related condition, and they did not have diabetes. The paper is available by DOI. Treatment lasted 72 weeks. Participants received one of three tirzepatide doses or placebo, alongside lifestyle guidance.

The main outcome was the average percent change in body weight. The results section reports mean reductions for each tirzepatide dose, and those reductions fell roughly in the range of 15 to 21 percent, compared with about 3 percent in the placebo group. Those figures come from the paper's results, so confirm the exact values in the tables before you quote them. Abstracts round numbers, and tables hold the detail. The paper also reports the share of participants who reached specific weight loss thresholds, and that share rose with dose. Read those numbers in the same tables.

Averages hide a lot. Some people lost far more than the average, some lost less, and a few lost very little. The trial also used strict selection rules, so the results describe a specific group of volunteers, not everyone who might take the drug. Keep that in mind when you see a dramatic before and after photo online.

What the trials did not measure (and what remains open)

Trials have limits. SURPASS-2 lasted 40 weeks and SURMOUNT-1 lasted 72 weeks, while many people use these medicines for much longer. The core trials could not show what happens to weight or blood sugar over years of use, or how quickly they change after stopping. Look for extension or maintenance publications if you want more on that point, and check their dates.

Populations were also restricted. The eligibility criteria in each registry entry list who was excluded, and the Mounjaro label gives specific guidance on pregnancy, boxed warnings, and contraindications. Ask your prescriber how those points apply to you rather than assuming the trial answers them.

Indirect comparisons are another gap. Tirzepatide has not been tested head to head against every drug in its class. When someone calls one medicine better based on separate trials, the designs may differ in population, duration, and outcome measures. Only direct comparisons, like SURPASS-2, answer that question for those two drugs in that setting. Long-term outcomes such as mortality and cardiovascular events for specific groups are also not fully answered by these trials. If you come across newer publications on those topics, read the methods before drawing conclusions. For more background on these open questions, the MounjaBlog archive covers many of them in plainer language.

How to read a study summary before your next doctor visit

A study summary can make your appointment more useful, as long as you treat it as a starting point rather than a verdict. Before you go in, note the trial name, the population studied, the duration, and the comparator. Then bring a short list of questions. Here are three to consider:

• Does the study population look like me in age, weight, and other health conditions?
• Which exclusion criteria in the registry might apply to my history?
• How does the study's treatment length compare with how long I would likely take this medicine?

Your prescriber can translate the data into your own plan. Avoid drawing conclusions about dose changes or stopping on your own. A trial shows what happened to a group under study conditions, while your doctor weighs your body, your lab results, and your goals. No medicine in this class is a cure. Tirzepatide can help with blood sugar control or weight loss as part of a broader plan that includes food, movement, and follow-up. Many readers also reread the MounjaBlog posts on their specific questions before a visit, and that habit can make the conversation sharper.

FAQ

Does tirzepatide work better than semaglutide?

In SURPASS-2, tirzepatide lowered HbA1c more than semaglutide 1 mg in adults with type 2 diabetes, at all three tested doses. That result doesn't mean it's the best choice for everyone, so discuss your situation with your doctor.

Did the SURMOUNT trials include people without diabetes?

Yes. SURMOUNT-1 enrolled adults with obesity or overweight plus at least one weight-related condition, and participants did not have diabetes.

Are trial results the same as results in everyday use?

Not exactly. Trials use strict eligibility rules, fixed doses, close monitoring, and set durations. Real treatment involves dose adjustments, different health histories, and varied habits.

Where can I check a tirzepatide trial's registration?

Search for the trial on ClinicalTrials.gov using its NCT number, then compare the registry entry with the published paper. Confirm any registration number on the registry page itself.

Does tirzepatide cure obesity or diabetes?

No. It can help with blood sugar control or weight loss when used as part of medical follow-up, but it is not a cure.

Sources

• Frías et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2), New England Journal of Medicine, 2021
• Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022
• ClinicalTrials.gov, SURPASS-2 registry entry NCT04037566
• ClinicalTrials.gov, SURMOUNT-1 registry entry NCT04184622
• U.S. FDA, Mounjaro (tirzepatide) prescribing information
• Anvisa, Bulário Eletrônico (bulas de medicamentos)